RT Journal Article
T1 Polypropylene and polyvinylidene fluoride transobturator slings for the treatment of female stress urinary incontinence: 1-Year outcomes from a multicentre randomized trial.
A1 Sabadell, Jordi
A1 Pereda-Núñez, Anna
A1 Ojeda-de-Los-Santos, Fernando
A1 Urbaneja, Manuel
A1 González-García, Carmen
A1 Camps-Lloveras, Narcís
A1 Pérez-Plantado, Àngela
A1 Canet-Rodríguez, Judit
A1 Pérez-Espejo, Maria Paz
A1 Rodríguez-Mias, Nuria
A1 Sarasa-Castelló, Núria
A1 Palau, Marta
A1 Montero-Armengol, Anabel
A1 Salicrú, Sabina
A1 Gil-Moreno, Antonio
A1 Poza, Jose L
K1 PVDF
K1 de novo urgency incontinence
K1 midurethral sling
K1 polypropylene
K1 polyvinylidene fluoride
K1 sling complications
K1 stress urinary incontinence
K1 suburethral sling
K1 suburethral tape
K1 transobturator
AB To compare the effectiveness and safety of polypropylene (PP) and polyvinylidene fluoride (PVDF) transobturator tapes (TOT) for the treatment of female stress urinary incontinence (SUI). This is a multicentre randomized trial. Women with SUI or stress-predominant mixed urinary incontinence and scheduled for a TOT procedure were randomized to PP or PVDF slings. The primary outcome was 1-year cure or improvement rate using composite criteria. Complications were also compared. Relationships with outcomes were analyzed using multivariable logistic regressions models. From April 2016 to January 2018 285 participants were randomized. PP and PVDF slings showed similar high cure or improvement rate (91.0% vs. 95.6%, p = .138). Improvement in validated questionnaires was also similar. PVDF slings were associated with a lower rate of de novo urgency incontinence (adjusted odds ratio = 0.35; 95% confidence interval = 0.15-0.80). We found no statistical differences in complications rates, although a higher incidence of long-term pain events were observed in the PP group. The study is underpowered to find differences in specific complications owing to the low number of events. PP and PVDF TOTs are equally effective, although PVDF is associated with fewer cases of de novo urgency incontinence. Further studies are needed to give robust conclusions on safety profiles.
YR 2020
FD 2020-12-01
LK http://hdl.handle.net/10668/16706
UL http://hdl.handle.net/10668/16706
LA en
DS RISalud
RD Apr 8, 2025